Your browser doesn't support javascript.
loading
Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly.
Marques-Pamies, Montserrat; Gil, Joan; Valassi, Elena; Hernández, Marta; Biagetti, Betina; Giménez-Palop, Olga; Martínez, Silvia; Carrato, Cristina; Pons, Laura; Villar-Taibo, Rocío; Araujo-Castro, Marta; Blanco, Concepción; Simón, Inmaculada; Simó-Servat, Andreu; Xifra, Gemma; Vázquez, Federico; Pavón, Isabel; García-Centeno, Rogelio; Zavala, Roxana; Hanzu, Felicia Alexandra; Mora, Mireia; Aulinas, Anna; Vilarrasa, Nuria; Librizzi, Soledad; Calatayud, María; de Miguel, Paz; Alvarez-Escola, Cristina; Picó, Antonio; Sampedro, Miguel; Salinas, Isabel; Fajardo-Montañana, Carmen; Cámara, Rosa; Bernabéu, Ignacio; Jordà, Mireia; Webb, Susan M; Marazuela, Mónica; Puig-Domingo, Manel.
Afiliação
  • Marques-Pamies M; Department of Endocrinology and Nutrition, Hospital Municipal de Badalona, Badalona, Spain.
  • Gil J; Endocrine Research Unit, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
  • Valassi E; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
  • Hernández M; Endocrine Research Unit, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
  • Biagetti B; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
  • Giménez-Palop O; Department of Endocrinology and Nutrition, Germans Trias i Pujol University Hospital, Badalona, Spain.
  • Martínez S; Department of Endocrinology and Nutrition, Arnau de Vilanova University Hospital, Lleida, Spain.
  • Carrato C; Endocrine Research Unit, Lleida Institute for Biomedical Research Dr. Pifarré Foundation (IRBLleida), Lleida, Spain.
  • Pons L; Department of Endocrinology and Nutrition, Vall Hebron University Hospital, Barcelona, Spain.
  • Villar-Taibo R; Department of Endocrinology and Nutrition, Parc Taulí University Hospital, Sabadell, Spain.
  • Araujo-Castro M; Department Hormonal Laboratory, Germans Trias i Pujol University Hospital, Badalona, Spain.
  • Blanco C; Department of Pathology, Germans Trias i Pujol University Hospital, Badalona, Spain.
  • Simón I; Department of Pathology, Germans Trias i Pujol University Hospital, Badalona, Spain.
  • Simó-Servat A; Department of Endocrinology and Nutrition, Clínico de Santiago University Hospital, Santiago de Compostela, Spain.
  • Xifra G; Department of Endocrinology and Nutrition, Ramón y Cajal University Hospital, Madrid, Spain.
  • Vázquez F; Department of Endocrinology and Nutrition, Príncipe de Asturias University Hospital, Madrid, Spain.
  • Pavón I; Department of Endocrinology and Nutrition, Joan XXIII University Hospital, Tarragona, Spain.
  • García-Centeno R; Department of Endocrinology and Nutrition, Mutua de Terrassa University Hospital, Terrassa, Spain.
  • Zavala R; Department of Endocrinology and Nutrition, Josep Trueta University Hospital, Girona, Spain.
  • Hanzu FA; Department of Endocrinology and Nutrition, Germans Trias i Pujol University Hospital, Badalona, Spain.
  • Mora M; Department of Endocrinology and Nutrition, Getafe University Hospital, Madrid, Spain.
  • Aulinas A; Department of Endocrinology and Nutrition, Gregorio Marañón University Hospital, Madrid, Spain.
  • Vilarrasa N; Department of Endocrinology and Nutrition, Joan XXIII University Hospital, Tarragona, Spain.
  • Librizzi S; Department of Endocrinology and Nutrition, Hospital Clinic University Hospital, Barcelona, Spain.
  • Calatayud M; Endocrine Research Unit, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
  • de Miguel P; Department of Endocrinology and Nutrition, Hospital Clinic University Hospital, Barcelona, Spain.
  • Alvarez-Escola C; Endocrine Research Unit, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
  • Picó A; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
  • Sampedro M; Department of Endocrinology and Nutrition, Hospital Sant Pau, Barcelona, Spain.
  • Salinas I; Universitat Autònoma de Barcelona (UAB), Departament de Medicina, Barcelona, Spain.
  • Fajardo-Montañana C; Department of Endocrinology and Nutrition, Bellvitge University Hospital, Bellvitge, Spain.
  • Cámara R; Endocrine Research Unit, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Bellvitge, Spain.
  • Bernabéu I; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
  • Jordà M; Department of Endocrinology and Nutrition, 12 de Octubre University Hospital, Madrid, Spain.
  • Webb SM; Department of Endocrinology and Nutrition, 12 de Octubre University Hospital, Madrid, Spain.
  • Marazuela M; Department of Endocrinology and Nutrition, Clínico San Carlos University Hospital, Madrid, Spain.
  • Puig-Domingo M; Department of Endocrinology and Nutrition, La Paz University Hospital, Madrid, Spain.
Front Endocrinol (Lausanne) ; 14: 1269787, 2023.
Article em En | MEDLINE | ID: mdl-38027102
Introduction: We previously described that a short version of the acute octreotide test (sAOT) can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients with acromegaly. We have prospectively reassessed the sAOT in patients from the ACROFAST study using current ultra-sensitive GH assays. We also studied the correlation of sAOT with tumor expression of E-cadherin and somatostatin receptor 2 (SSTR2) . Methods: A total of 47 patients treated with SRLs for 6 months were evaluated with the sAOT at diagnosis and correlated with SRLs' response. Those patients whose IGF1 decreased to <3SDS from normal value were considered responders and those whose IGF1 was ≥3SDS, were considered non-responders. The 2 hours GH value (GH2h) after s.c. administration of 100 mcg of octreotide was used to define predictive cutoffs. E-cadherin and SSTR2 immunostaining in somatotropinoma tissue were investigated in 24/47 and 18/47 patients, respectively. Results: In all, 30 patients were responders and 17 were non-responders. GH2h was 0.68 (0.25-1.98) ng/mL in responders vs 2.35 (1.59-9.37) ng/mL in non-responders (p<0.001). GH2h = 1.4ng/mL showed the highest ability to identify responders (accuracy of 81%, sensitivity of 73.3%, and specificity of 94.1%). GH2h = 4.3ng/mL was the best cutoff for non-response prediction (accuracy of 74%, sensitivity of 35.3%, and specificity of 96.7%). Patients with E-cadherin-positive tumors showed a lower GH2h than those with E-cadherin-negative tumors [0.9 (0.3-2.1) vs 3.3 (1.5-12.1) ng/mL; p<0.01], and patients with positive E-cadherin presented a higher score of SSTR2 (7.5 ± 4.2 vs 3.3 ± 2.1; p=0.01). Conclusion: The sAOT is a good predictor tool for assessing response to SRLs and correlates with tumor E-cadherin and SSTR2 expression. Thus, it can be useful in clinical practice for therapeutic decision-making in patients with acromegaly.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Hipofisárias / Acromegalia / Adenoma Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Hipofisárias / Acromegalia / Adenoma Idioma: En Ano de publicação: 2023 Tipo de documento: Article